Interim Management Statement

RNS Number : 3114L

Dechra Pharmaceuticals PLC

05 May 2010

 



Issued by Citigate Dewe Rogerson Ltd, Birmingham

Date: Wednesday, 5 May 2010

Dechra^® Pharmaceuticals PLC

Interim Management Statement

Dechra Pharmaceuticals PLC ("Dechra" or the "Group"), publishes its Interim Management Statement covering the period from 1 January 2010 to the date of this announcement.

Overall trading in the third quarter of the current financial year has continued to be positive despite the disruption caused by the poor weather in January.  Group revenue for the three months ended 31 March 2010 was 5.7% ahead of last year.  For the nine months ended 31 March 2010, Group revenue increased by 6.3% over the corresponding period in the prior year.

In the third quarter, European Pharmaceuticals revenue grew by 6.3% compared to the same period last year.  For the nine months to 31 March 2010 revenue was ahead of last year by 7.0%.

Revenue from US Pharmaceuticals was ahead of last year by 11.7% in the third quarter and by 46.4% for the nine months ended 31 March 2010.  Revenue from Vetoryl^® was $1.9 million in the third quarter and $4.4 million in the year to date.

There have been a number of advancements in our product portfolio.  Vetoryl has received notification of approval for Japan; Urilin^®, our branded UK generic for urinary incontinence in dogs, has received approval in the EU; Flexicam^® Injection, an extension to our canine pain relief range, has also received EU approval; and we have been notified by the FDA that the safety and manufacturing control sections for Equidone^®, our specialist equine product for the US market, are complete.  Furthermore, we have secured the US marketing rights for Ovuplant^®, a specialist equine fertility drug which we currently market in the EU.

The Services division increased revenues in the third quarter by 4.4%.  Revenue for the nine months ended 31 March 2010 was 4.6% ahead of the equivalent period last year.

Other than as noted above, there have been no material events or transactions between 1 January 2010 and the date of this announcement.

Trading remains in line with the Board's expectations and we remain confident that the Group will continue to make good strategic progress throughout the remainder of the financial year.

Enquiries:
Ian Page, Chief Executive	Fiona Tooley, Director
Simon Evans, Group Finance Director	Keith Gabriel, Senior Account Manager
Dechra Pharmaceuticals PLC	Citigate Dewe Rogerson
Tel: [phone]	Tel: [phone]
Mobile: [phone] (IP)	Mobile: [phone] (FMT)
Mobile: [phone] (SE)	Mobile: [phone] (KG)
www.dechra.com
[e-mail]

Trademarks appear throughout this release in italics.  Dechra and the Dechra 'D' logo are registered Trademarks of Dechra Pharmaceuticals PLC.

 

END

 

 

IMSLLFSEEIISIII